Trastuzumab’s Fc domain is recognized by homologous Fc receptors on natural killer cells, resulting in ADCC and the destruction or phagocytosis of HER2-positive tumor cells that are tagged by trastuzumab [39]. The gene discussed is ERBB2; the disease is neoplasm.